Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC
Emma Wall, Mary Wu, Ruth Harvey, et al.
The Lancet (2021) Vol. 398, Iss. 10296, pp. 207-209
Open Access | Times Cited: 128

Showing 1-25 of 128 citing articles:

SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway
Brian J. Willett, Joe Grove, Oscar A. MacLean, et al.
Nature Microbiology (2022) Vol. 7, Iss. 8, pp. 1161-1179
Open Access | Times Cited: 531
Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis
Deborah Cromer, Megan Steain, Arnold Reynaldi, et al.
The Lancet Microbe (2021) Vol. 3, Iss. 1, pp. e52-e61
Open Access | Times Cited: 340
Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action
Franz X. Heinz, Karin Stiasny
npj Vaccines (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 339
Global landscape of SARS-CoV-2 genomic surveillance and data sharing
Zhiyuan Chen, Andrew S. Azman, Xinhua Chen, et al.
Nature Genetics (2022) Vol. 54, Iss. 4, pp. 499-507
Open Access | Times Cited: 226
Impact of the Delta variant on vaccine efficacy and response strategies
Lianlian Bian, Qiushuang Gao, Fan Gao, et al.
Expert Review of Vaccines (2021) Vol. 20, Iss. 10, pp. 1201-1209
Open Access | Times Cited: 215
The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance
Izumi Kimura, Yusuke Kosugi, Jiaqi Wu, et al.
Cell Reports (2021) Vol. 38, Iss. 2, pp. 110218-110218
Open Access | Times Cited: 180
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
Annika Fendler, Elisabeth G.E. de Vries, Corine H. GeurtsvanKessel, et al.
Nature Reviews Clinical Oncology (2022) Vol. 19, Iss. 6, pp. 385-401
Open Access | Times Cited: 178
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study
Annika Fendler, Scott T.C. Shepherd, Lewis Au, et al.
Nature Cancer (2021) Vol. 2, Iss. 12, pp. 1305-1320
Open Access | Times Cited: 158
Immunity to SARS‐CoV‐2 induced by infection or vaccination
Xaquín Castro Dopico, Sebastian Ols, Karin Loré, et al.
Journal of Internal Medicine (2021) Vol. 291, Iss. 1, pp. 32-50
Open Access | Times Cited: 145
Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies
Takuya Tada, Hao Zhou, Belinda M. Dcosta, et al.
EBioMedicine (2022) Vol. 78, pp. 103944-103944
Open Access | Times Cited: 137
The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism
Brian J. Willett, Joe Grove, Oscar A. MacLean, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 135
Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern
Liane Dupont, Luke B. Snell, Carl Graham, et al.
Nature Microbiology (2021) Vol. 6, Iss. 11, pp. 1433-1442
Open Access | Times Cited: 104
Three-dose vaccination elicits neutralising antibodies against omicron
Mary Wu, Emma Wall, Edward J Carr, et al.
The Lancet (2022) Vol. 399, Iss. 10326, pp. 715-717
Open Access | Times Cited: 91
SARS-CoV-2 S2–targeted vaccination elicits broadly neutralizing antibodies
Kevin W. Ng, Nikhil Faulkner, Katja Finsterbusch, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 655
Open Access | Times Cited: 85
The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern
Hikmet Akkız
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 82
Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer
Annika Fendler, Scott T.C. Shepherd, Lewis Au, et al.
The Lancet (2022) Vol. 399, Iss. 10328, pp. 905-907
Open Access | Times Cited: 81
SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease
Eleanor Barnes, Carl S. Goodyear, Michelle Willicombe, et al.
Nature Medicine (2023) Vol. 29, Iss. 7, pp. 1760-1774
Open Access | Times Cited: 80
The Delta and Omicron Variants of SARS-CoV-2: What We Know So Far
Vivek P. Chavda, Rajashri Bezbaruah, Kangkan Deka, et al.
Vaccines (2022) Vol. 10, Iss. 11, pp. 1926-1926
Open Access | Times Cited: 72
SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance
Izumi Kimura, Yusuke Kosugi, Jiaqi Wu, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Closed Access | Times Cited: 96
Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients
Edward J Carr, Mary Wu, Ruth Harvey, et al.
The Lancet (2021) Vol. 398, Iss. 10305, pp. 1038-1041
Open Access | Times Cited: 85
Vaccine Effectiveness Studies in the Field
Stephen Evans, Nicholas P. Jewell
New England Journal of Medicine (2021) Vol. 385, Iss. 7, pp. 650-651
Open Access | Times Cited: 69
Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination
Haya Altawalah
Vaccines (2021) Vol. 9, Iss. 8, pp. 910-910
Open Access | Times Cited: 69
SARS-CoV-2 variants, immune escape, and countermeasures
Yi Zhang, Haocheng Zhang, Wenhong Zhang
Frontiers of Medicine (2022) Vol. 16, Iss. 2, pp. 196-207
Open Access | Times Cited: 65
A systematic review of Vaccine Breakthrough Infections by SARS-CoV-2 Delta Variant
Mengxin Zhang, Ying Liang, Dongsheng Yu, et al.
International Journal of Biological Sciences (2022) Vol. 18, Iss. 2, pp. 889-900
Open Access | Times Cited: 60
Clinical development and approval of COVID-19 vaccines
Ulrich Kalinke, Dan H. Barouch, Ruben Rizzi, et al.
Expert Review of Vaccines (2022) Vol. 21, Iss. 5, pp. 609-619
Open Access | Times Cited: 55
Page 1 - Next Page

Scroll to top